Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer

Gunay F. S. D., KIRMIZI B. A., ENSARİ A., Icli F., AKBULUT H.

CLINICAL COLORECTAL CANCER, cilt.18, sa.2, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clcc.2018.12.004
  • Dergi Adı: CLINICAL COLORECTAL CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Bevacizumab, Biomarker, Colorectal cancer, Neuroendocrine differentiation, Tumor-associated macrophages, PROGNOSTIC-FACTOR, PROGRESSION, BIOMARKERS
  • Ankara Üniversitesi Adresli: Evet

Özet

No predictive marker is available for antiangiogenic treatment modalities in routine practice. The present study included a group of patients with advanced colorectal cancer, including 123 consecutive patients treated with bevacizumab plus chemotherapy, to determine the predictive and prognostic role of tumor-associated macrophages (TAMs) and neuroendocrine differentiation (NED) of primary tumor tissue. High TAM infiltration and the presence of NED in tumor tissue were predictors for poor survival.